Atnaujinkite slapukų nuostatas

Cannabinoid Pharmacology, Volume 80 [Kietas viršelis]

Volume editor (University of Nottingham Medical School, Nottingham, UK), Volume editor (Nottingham University, Nottingham, UK)
  • Formatas: Hardback, 492 pages, aukštis x plotis: 229x152 mm, weight: 970 g
  • Serija: Advances in Pharmacology
  • Išleidimo metai: 24-Aug-2017
  • Leidėjas: Academic Press Inc
  • ISBN-10: 0128112328
  • ISBN-13: 9780128112328
Kitos knygos pagal šią temą:
Cannabinoid Pharmacology, Volume 80Didesnis paveikslėlis
  • Formatas: Hardback, 492 pages, aukštis x plotis: 229x152 mm, weight: 970 g
  • Serija: Advances in Pharmacology
  • Išleidimo metai: 24-Aug-2017
  • Leidėjas: Academic Press Inc
  • ISBN-10: 0128112328
  • ISBN-13: 9780128112328
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780128112328.html
Raktažodžiai:

Cannabinoid Pharmacology, Volume 80 is a new volume in the Advances in Pharmacology that presents reviews of recent breakthroughs. This volume aims to present current knowledge of the endogenous cannabinoid system, and looks at molecular, cellular, tissue and organismal effects of endogenous and exogenous cannabinoids. Topics of note in this new volume include Endocannabinoids and their congeners, Endocannabinoid turnover, Plant cannabinoids, Synthetic cannabinoids and ‘legal highs’, CB1 and CB2 cannabinoid receptors, Novel signaling modalities, Novel cannabinoid receptors, and Ion channel regulation by cannabinoids.

There is a broad coverage of the essential elements associated with the cannabinoid system. The Editors have sought to include authors who represent authoritative voices on these themes, but have not previously worked together to allow a fresh approach to the individual aspects covered.

  • Presents reviews of recent breakthroughs in the cannabinoid system
  • Features chapters from the best authors in the field
  • Provides an essential resource for scientists, advanced undergraduate students through to established faculty members

Daugiau informacijos

A critical assessment of molecular, cellular, tissue and organismal effects of endogenous and exogenous cannabinoids
Contributors xi
Preface xv
1 Endocannabinoid Analytical Methodologies: Techniques That Drive Discoveries That Drive Techniques
1(30)
Fabiana Piscitelli
Heather B. Bradshaw
1 Introduction
2(3)
2 Mass Spectrometry-Based Techniques for Lipidomics Approaches Applied to the Endocannabinoidome
5(1)
3 Overview of Analytical Methodologies for eCBs Extraction and Quantification
5(6)
4 Advances in Expanding the Coverage of the Endocannabinoidome Using "Endocannabinoidomics"
11(3)
5 Measuring eCBs Drove Discovery of Lipoamines and Additional Mono Acylglyerols
14(7)
6 Conclusion
21(10)
Conflict of Interest
21(1)
References
21(10)
2 Endocannabinoid Turnover
31(36)
Christopher J. Fowler
Patrick Doherty
Stephen P.H. Alexander
1 Introduction
32(1)
2 Biosynthesis of AEA and Related N-Acylethanolamine
32(4)
3 Diacylglycerol Lipase-Dependent Synthesis of 2-AG
36(2)
4 2-AG, AA, and AEA Levels in DAGL Knockout Mice
38(2)
5 Pharmacological Inhibition of the DAGLs Mimics the Knockout Results
40(1)
6 DAGL-Dependent Endocannabinoid Signaling Regulates Synaptic Function
41(2)
7 Release and Reuptake of Endocannabinoids
43(1)
8 Enzymatic Hydrolysis of AEA and Related NAEs
44(1)
9 Enzymatic Hydrolysis of 2-AG and Related Monoacylglycerols
45(2)
10 Pharmacological Inhibitors of Monoacylglycerol Hydrolase Activities
47(2)
11 Oxidative Metabolism of Endocannabinoids
49(1)
12 Integrating the Catabolism of the Endocannabinoids and Related NAEs in Health and Disease
50(3)
13 Conclusion
53(14)
Conflict of Interest
53(1)
Acknowledgments
53(1)
References
54(13)
3 Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads
67(68)
Ethan B. Russo
Jahan Marcu
1 Introduction
69(1)
2 Cannabis Phytocannabinoids
70(13)
3 Cannabis Terpenoids
83(1)
4 Cannabis Monoterpenoids
84(14)
5 Cannabis Sesquiterpenoids
98(8)
6 Cannabis Odds and Ends: Root Triterpenoids and Alkaloids, Leaf Flavonoids, Seed Coats, and Sprouts
106(5)
7 Conclusion
111(24)
Conflict of Interest
111(1)
Acknowledgments
112(1)
References
112(23)
4 Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events
135(34)
Colin Davidson
Jolanta Opacka-Juffry
Angel Arevalo-Martin
Daniel Garcia-Ovejero
Eduardo Molina-Holgado
Francisco Molina-Holgado
1 The Cannabinoid System, Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids
136(2)
2 Signaling Pathways Associated to SCB
138(2)
3 Structural Classification of SCB
140(5)
4 Cannabinoid/CB, Receptors Involvement in Memory Regulation and Psychosis
145(6)
5 Clinical Adverse Effects of SCB
151(7)
6 Conclusion
158(11)
Conflict of Interest
158(1)
References
158(8)
Further Reading
166(3)
5 CB, and CB2 Receptor Pharmacology
169(38)
Allyn C. Howlett
Mary E. Abood
1 Introduction
170(1)
2 Pharmacological Characterization
171(1)
3 Natural Polymorphisms and Alternative Splice Variants
172(4)
4 Phylogeny
176(2)
5 Distribution
178(1)
6 Cannabinoid Receptor Signaling Pathways Associated With Differentiated Tissues
179(11)
7 Extended Agonist Exposure
190(1)
8 Agonist-Biased Signaling: Targeting Receptor Conformations Leading to Selective Pharmacological Responses
191(3)
9 Conclusion
194(13)
Conflict of Interest
194(1)
Acknowledgments
194(1)
References
194(13)
6 Functional Selectivity at Cannabinoid Receptors
207(16)
Richard Priestley
Michelle Glass
David Kendall
1 Introduction
208(1)
2 Why Does Functional Selectivity Matter?
209(1)
3 Determination of Functional Selectivity
210(1)
4 Functional Selectivity at Cannabinoid Receptors
211(2)
5 Cannabinoid Receptor Agonist-Selective Signaling
213(3)
6 Functional Selectivity in Complex Systems
216(1)
7 Mechanisms of Functional Selectivity
217(1)
8 Conclusion
218(5)
Conflict of Interest
218(1)
References
219(4)
7 Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors
223(26)
Andrew Irving
Ghayth Abdulrazzaq
Sue L.F. Chan
June Penman
Jenni Harvey
Stephen P.H. Alexander
1 Introduction
224(1)
2 Evidence for Novel Cannabinoid Receptor-Like GPCR Targets
225(2)
3 GPR18 as a Cannabinoid Receptor-Like GPCR
227(5)
4 GPR55 as a Cannabinoid Receptor-Like GPCR
232(6)
5 GPR119 as a Cannabinoid Receptor-Like GPCR
238(2)
6 Conclusion
240(9)
Conflict of Interest
240(1)
Acknowledgment
241(1)
References
241(8)
8 Actions and Regulation of Ionotropic Cannabinoid Receptors
249(42)
Luciano De Petrocellis
Massimo Nabissi
Giorgio Santoni
Alessia Ligresti
1 Introduction
250(3)
2 TRPV Channels and Cannabinoid-Mediated Regulation
253(5)
3 TRPA Channels and Cannabinoid-Mediated Regulation
258(4)
4 TRPM Channels and Cannabinoid-Mediated Regulation
262(6)
5 TRPC Channels and Cannabinoid-Mediated Regulation
268(3)
6 Non-TRP Ion Channels and Cannabinoid-Mediated Regulation
271(3)
7 Conclusion
274(17)
Conflict of Interest
274(1)
References
274(17)
9 The Role of Nuclear Hormone Receptors in Cannabinoid Function
291(38)
Marco Pistis
Saoirse E. O'Sullivan
1 Introduction
292(1)
2 PPARa
293(8)
3 PPARy
301(6)
4 PPARβ/δ
307(2)
5 Modulation of the Endocannabinoid System and PPAR Activation
309(1)
6 Other Nuclear Hormone Receptors
310(2)
7 Conclusion
312(17)
Conflict of Interest
314(1)
References
314(15)
10 Cannabinoids in the Cardiovascular System
329(38)
Wing S.V. Ho
Melanie E.M. Kelly
1 Introduction
330(2)
2 Cardiovascular Effects of Cannabinoids
332(7)
3 Endocannabinoid Metabolites
339(1)
4 Endocannabinoid Congeners
339(1)
5 Targeting the ECS in Cardiovascular Diseases
340(10)
6 Clinical Trials of CB1R Antagonists, CB2R Agonists and FAAH Inhibitors
350(2)
7 Conclusion
352(15)
Conflict of Interest
353(1)
Acknowledgments
353(1)
References
353(14)
11 Is the Cannabinoid CB2 Receptor a Major Regulator of the Neuroinflammatory Axis of the Neurovascular Unit in Humans?
367(30)
Dan T. Kho
Michelle Glass
Euan S. Graham
1 Introduction
368(4)
2 The NVU and the BBB
372(5)
3 Evidence for the Expression of CB2 by the NVU and BBB
377(3)
4 Evidence of the Regulation of NVU Functions by Cannabinoids
380(5)
5 Conclusion
385(12)
Conflict of Interest
387(1)
References
387(10)
12 Cannabinoids as Anticancer Drugs
397(40)
Robert Ramer
Burkhard Hinz
1 Introduction
399(4)
2 Modulation of the Endocannabinoid System in Tumor Progression
403(3)
3 The Role of the Endocannabinoid System in Cancer Progression and Potential Pharmacological Options of Cannabinoid Compounds
406(13)
4 Inhibition of Endocannabinoid-Degrading Enzymes as Anticancer Strategy
419(2)
5 Conclusion
421(16)
Conflict of Interest
424(1)
References
424(13)
13 Cannabinoids and Pain: Sites and Mechanisms of Action
437(38)
Katarzyna Starowicz
David P. Finn
1 Introduction
438(7)
2 Anatomical Localization of the Endocannabinoid System Throughout the Pain Pathway
445(4)
3 Supraspinal Sites and Mechanisms of Action
449(6)
4 Spinal Sites and Mechanisms of Action
455(3)
5 Peripheral Sites and Mechanisms of Action
458(3)
6 Conclusion
461(14)
Conflict of Interest
462(1)
Acknowledgments
462(1)
References
462(13)
Further Reading 475
David Kendall has had an active interest in cannabinoid research for over 20 years focussing initially on endocannabinoid signalling in the vascular system and latterly in its roles in pain. He was Professor of Pharmacology in the University of Nottingham Medical School until 2015 before taking up the position of Chief Scientific Officer for the drug discovery company PharmNovo. Dr Stephen Alexander has been interested in the regulation of mammalian cannabinoid systems since the first identification of an endogenous cannabinoid molecule in 1993. He has principally focused on the enzymes associated with the hydrolysis and transformation of these endocannabinoids, both in terms of establishing high throughput assays for these enzymes and also in quantifying their activities in tissues ex vivo. He is an Associate Professor of Molecular Pharmacology at the University of Nottingham, Chair of the Nomenclature Committee of the International Union of Basic and Clinical Pharmacology and has been President of the International Cannabinoid Research Society.